Allbirds' $39 Million Sale: A Cautionary Tale for the IPO Class of 2021

Related Articles

OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

1 months ago

Immunome's $4.39 Million Insider Sale: A Pre-Planned Exit Amidst Robust Pipeline Momentum

1 months ago

Congressional Contrasts: A Tale of Two Trades in Constellation Energy

3 months ago

The Bitcoin Rollercoaster: A Tale of Two Extremes

6 months ago

Category

You may also like

Stock News•1 week ago

Bending Spoons: One Of Europe's Hottest IPOs

Bending Spoons (BSP) raised $1.1 billion in its Nasdaq IPO, after posting 126% revenue growth driven by acquisitions like AOL, Eventbrite, and Vimeo. Organic growth was just 3%, raising sustainability...

BSP

Share

Stock News•1 week ago

Birkenstock Jumps 15% After Raising Sales Forecast

Birkenstock Holding plc rose nearly 15% after raising its full-year sales forecast, following third-quarter revenue that climbed 13%.

BIRK

Share

News•3 weeks ago

More consumer companies are staying private for longer, avoiding the IPO road

Consumer companies are staying private longer, with only a handful pursuing IPOs this year, as secondary markets and stronger liquidity reduce the need for public listings.

Share

Stock News•1 months ago

What Prediction Markets Say About 3 of America's Most At-Risk Brands

Prediction markets like Polymarket now track bankruptcy odds for consumer brands trading below $10, offering real-time distress signals for investors.

BYND

Share